Evidence map›Paper›PMID 36166646›Full record

ArticleCancer research2022

HOXA5-Mediated Stabilization of IκBα Inhibits the NF-κB Pathway and Suppresses Malignant Transformation of Breast Epithelial Cells.

Priya Pai, Guannan Wang, Wei Wen Teo, Diana Raez-Rodriguez, Kathleen L Gabrielson, Balázs Győrffy, Bradley M Downs, Akanksha Aggarwal, Saraswati Sukumar

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Priya PaiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1126-6248
Guannan WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-6973-2427
Wei Wen TeoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3647-0253
Diana Raez-RodriguezDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6342-1027
Kathleen L GabrielsonDepartment of Molecular and Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3901-4357
Balázs GyőrffySemmelweis University Department of Bioinformatics, Budapest, Hungary.ORCID 0000-0002-5772-3766
Bradley M DownsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-6156-510X
Akanksha AggarwalDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8986-2496
Saraswati SukumarDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5656-6703
Johns Hopkins University · USSemmelweis University · HU

Funding

Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2003 to 2015
$17.9M
NCI NIH HHS P50 CA103175
6 · The paper itself

Abstract

HOXA5 is a transcription factor and tumor suppressor that promotes differentiation of breast epithelial cells and is frequently lost during malignant transformation. HOXA5 loss alone, however, does not confer tumorigenicity. To determine which molecular alterations combined with loss of HOXA5 expression can transform cells, we examined isogenic derivatives of a nonmalignant breast epithelial cell line containing knock-in or knockout mutations in key breast cancer genes. Knockdown (KD) of HOXA5 in cells harboring double knock-in (DKI) of mutated PIK3CA (E545K) and HER2 (V777L) induced epithelial-mesenchymal transition and migration and promoted invasive tumor outgrowth within mouse mammary ducts. The NF-κB pathway was significantly upregulated in DKI cells following HOXA5 KD. HOXA5 KD upregulated multiple NF-κB target genes, including IL6. IκBα protein, but not RNA, expression was reduced in HOXA5-KD cells. HOXA5 bound and stabilized IκBα, forming a nuclear HOXA5-IκBα complex. Chromatin immunoprecipitation sequencing database queries revealed that HOXA5 and IκBα are co-enriched at 528 genomic loci. In patients with breast cancer, high coexpression of HOXA5 and IκBα conferred a significantly better overall and progression-free survival. Collectively, these data suggest that HOXA5 suppresses malignancy in breast epithelial cells by blunting NF-κB action via stabilization of its inhibitor IκBα. SIGNIFICANCE: Loss of HOXA5 reduces IκBα stability and increases NF-κB signaling to exacerbate breast cancer aggressiveness, providing new insights into the tumor suppressor functions of HOXA5.

Indexed as

Interleukin-6NF-kappa BAnimalsCell Line, TumorCell Transformation, NeoplasticClass I Phosphatidylinositol 3-KinasesEpithelial CellsHomeodomain ProteinsMiceNF-KappaB Inhibitor alphaTranscription FactorsClass I Phosphatidylinositol 3-KinasesHomeodomain ProteinsHoxa5 protein, mouseInterleukin-6NF-kappa BNF-KappaB Inhibitor alphaTranscription Factors

Identifiers

PMID36166646
PMCPMC9588663
OpenAlexW4297338596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.